The absolute risk was considered small [7], and the relatively modest impact of DPP-IV inhibition on the risk of ACEI-induced angioedema was ascribed to the presence of redundant enzymatic pathways implicated in the degradation of bradykinin and substance P [5]. This evidence concerns the gene DPP4 and angioedema.